June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Outcomes in Patients with Neovascular Age-related Macular Degeneration Based on Dosing Subgroups in the Second Year of the VIEW 1 and VIEW 2 Studies
Author Affiliations & Notes
  • Ehsan Rahimy
    Palo Alto Medical Foundation, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Ehsan Rahimy, Regeneron Pharmaceuticals, Inc. (C)
  • Footnotes
    Support  Regeneron Pharmaceuticals, Inc.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 908. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Ehsan Rahimy; Outcomes in Patients with Neovascular Age-related Macular Degeneration Based on Dosing Subgroups in the Second Year of the VIEW 1 and VIEW 2 Studies. Invest. Ophthalmol. Vis. Sci. 2017;58(8):908.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate outcomes in patients with neovascular age-related macular degeneration (AMD) during the second year (weeks 52-96) of treatment following fixed dosing during the first-year in the VIEW studies

Methods : During the first year patients received 0.5 mg intravitreal ranibizumab every 4 weeks (Rq4), 2 mg intravitreal aflibercept injection (IAI) every 4 weeks (2q4), 0.5 mg IAI every 4 weeks (0.5q4), or 2 mg IAI every 8 weeks following three monthly injections (2q8). In the second year of follow-up, patients received their randomized treatment assignment (IAI or ranibizumab) using a modified quarterly dosing regimen based on protocol-specified retreatment criteria with a mandatory dose at least every 12 weeks. Two subgroups of patients who received 0.5 mg ranibizumab and 2 mg IAI were evaluated for efficacy): 1) patients who only received injections at ≥12 week intervals (≥q12-week subgroup) 2) Patients who received at least one injection at <12 week interval (<12q-week subgroup). Only patients who completed 2 years of follow-up were included. Integrated data from VIEW studies are reported here.

Results : At week 96, 42.5%, 53.9%, and 47.9% of patients in the Rq4, 2q4, and 2q8 groups, respectively, were in the ≥q12-week subgroup. Corresponding proportions of patients in the (<12q-week subgroup were 57.5%, 46.1%, and 52.1%, respectively. Mean BCVA gains achieved at week 52 in both subgroups were largely maintained through week 96, and these outcomes were consistent with the BCVA gains for the total population (Table). Incidences of Antiplatelet Trialists’ Collaboration defined arterial thromboembolic events were similar across treatment groups (2.4% to 3.8%) from baseline to week 96.

Conclusions : A numerically higher proportion of patients treated with IAI received injections at ≥q12 week intervals compared to ranibizumab from week 52 to 96. Visual acuity gains achieved at week 52 were largely maintained through week 96 in both subgroups. These data indicate that many patients maintained their visual and anatomic improvements with dosing at ≥q12-week intervals following fixed dosing during the first year.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×